Rosiglitazone, PPARγ, and type 2 diabetes

N Engl J Med. 2010 Dec 30;363(27):2667-9. doi: 10.1056/NEJMcibr1012075.
No abstract available

MeSH terms

  • Cyclin-Dependent Kinase 5 / antagonists & inhibitors*
  • Cyclin-Dependent Kinase 5 / genetics
  • Cyclin-Dependent Kinase 5 / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / prevention & control*
  • Gene Expression
  • Hypoglycemic Agents / pharmacology*
  • Hypoglycemic Agents / therapeutic use
  • Obesity / metabolism
  • PPAR gamma / metabolism*
  • Phosphorylation / drug effects
  • Rosiglitazone
  • Thiazolidinediones / pharmacology*
  • Thiazolidinediones / therapeutic use

Substances

  • Hypoglycemic Agents
  • PPAR gamma
  • Thiazolidinediones
  • Rosiglitazone
  • Cyclin-Dependent Kinase 5